Evan J Levy,Matthew Cowan
Evan J Levy
The use of secondary cytoreductive surgery before standard chemotherapy in recurrent ovarian cancer is controversial. Several groups have identified patient and disease factors that correlate with benefit from surgery. Complete gross resect...
Connor C Wang,Maria Gomez-Roas,Emily M Hinchcliff
Connor C Wang
Recurrent platinum-resistant ovarian cancer represents a significant therapeutic challenge, characterized by poor responses to standard chemotherapy and limited survival outcomes. This chapter comprehensively reviews the biological mechanis...
Jeffrey D Wayne
Jeffrey D Wayne
Dario R Roque
Dario R Roque
Measurable/Minimal Residual Disease: What Method and What Cut-Off? [0.03%]
measurable/ MRD：使用何种方法以及临界值如何确定？
Andrew Rawstron
Andrew Rawstron
Minimal residual disease (MRD) testing has become a central response biomarker in clinical trials of time-limited treatment, with MRD-guided strategies under increasing evaluation. This article compares key technical and practical features ...
Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia [0.03%]
慢性淋巴细胞白血病的感染并发症的理解与处理
Noomi Vainer,Andreas Katsimigas,Emelie Curovic Rotbain et al.
Noomi Vainer et al.
Despite major improvements in the treatment landscape of chronic lymphocytic leukemia (CLL), infections remain the major cause of death for patients with CLL. Management of infections in patients with CLL includes antimicrobial therapy, pro...
Jacob D Soumerai,Matthew S Davids
Jacob D Soumerai
Triplet therapy regimens, which we define as the combination of a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib), BCL2 inhibitor (venetoclax or sonrotoclax), and a CD20 antibody (obinutuzumab), have been developed ...
Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia [0.03%]
慢性淋巴细胞性白血病中理解并靶向BCL2抑制剂耐药性
Alexander F Vom Stein,Lukas P Frenzel
Alexander F Vom Stein
Chronic lymphocytic leukemia (CLL) treatment has evolved with the introduction of venetoclax, a selective BCL-2 inhibitor capable of inducing apoptosis in CLL cells. However, resistance has emerged as a significant clinical obstacle. Here, ...
Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia [0.03%]
慢性淋巴细胞性白血病中B细胞受体的自主信号转导
Anastasia Iatrou,Andreas Agathangelidis,Jessica Bordini et al.
Anastasia Iatrou et al.
Chronic lymphocytic leukemia (CLL) is driven by both antigen-dependent and antigen-independent cell-autonomous B-cell receptor (BcR) signaling. The latter has been documented in CLL cases in different disease subgroups and correlates with d...
Allison Kagerer,Meghan C Thompson
Allison Kagerer
Covalent Bruton's tyrosine kinase inhibitors (cBTKis), including acalabrutinib and zanubrutinib, and the BCL2 inhibitor venetoclax are currently sequenced in both front-line and relapsed and/or refractory (R/R) chronic lymphocytic leukemia ...